Brokerages expect that Heron Therapeutics Inc (NASDAQ:HRTX) will post $33.93 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Heron Therapeutics’ earnings, with estimates ranging from $30.00 million to $38.00 million. Heron Therapeutics reported sales of $19.79 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 71.5%. The company is expected to announce its next earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Heron Therapeutics will report full-year sales of $129.34 million for the current financial year, with estimates ranging from $124.00 million to $139.30 million. For the next year, analysts forecast that the company will post sales of $175.10 million, with estimates ranging from $122.70 million to $253.70 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. The company had revenue of $36.66 million for the quarter, compared to analysts’ expectations of $31.04 million.
Several analysts recently weighed in on HRTX shares. Stifel Nicolaus reissued a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a research note on Monday, August 5th. Evercore ISI reissued a “buy” rating and issued a $75.00 price objective on shares of Heron Therapeutics in a research note on Tuesday, August 13th. Cowen reissued a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research note on Tuesday, October 1st. Zacks Investment Research raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. Finally, BidaskClub cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 26th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $50.57.
Shares of Heron Therapeutics stock traded up $1.17 during trading on Friday, hitting $20.98. The company’s stock had a trading volume of 71,574 shares, compared to its average volume of 1,322,903. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.01 and a quick ratio of 3.70. Heron Therapeutics has a 52 week low of $15.68 and a 52 week high of $31.81. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -8.60 and a beta of 1.42. The stock has a 50-day moving average price of $18.95 and a two-hundred day moving average price of $18.88.
In other news, insider John Poyhonen purchased 11,105 shares of the business’s stock in a transaction on Monday, September 30th. The shares were acquired at an average price of $22.62 per share, with a total value of $251,195.10. Also, CEO Barry D. Quart purchased 4,571 shares of the business’s stock in a transaction on Thursday, October 3rd. The shares were purchased at an average cost of $17.50 per share, for a total transaction of $79,992.50. Following the transaction, the chief executive officer now directly owns 90,081 shares of the company’s stock, valued at approximately $1,576,417.50. The disclosure for this purchase can be found here. Insiders have acquired 306,533 shares of company stock worth $5,421,185 in the last ninety days. Insiders own 12.56% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers boosted its position in Heron Therapeutics by 1.1% during the third quarter. Rhumbline Advisers now owns 100,802 shares of the biotechnology company’s stock valued at $1,865,000 after acquiring an additional 1,124 shares during the last quarter. Chartwell Investment Partners LLC boosted its position in Heron Therapeutics by 1.1% during the second quarter. Chartwell Investment Partners LLC now owns 100,171 shares of the biotechnology company’s stock valued at $1,862,000 after acquiring an additional 1,129 shares during the last quarter. Meadow Creek Investment Management LLC bought a new stake in Heron Therapeutics during the second quarter valued at $27,000. Congress Park Capital LLC boosted its position in shares of Heron Therapeutics by 1.5% during the 3rd quarter. Congress Park Capital LLC now owns 111,265 shares of the biotechnology company’s stock worth $2,058,000 after purchasing an additional 1,600 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of Heron Therapeutics by 75.6% during the 2nd quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,769 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Further Reading: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.